Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptamxg1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 8	JAN 30	Saved answer limit increased
NEWS 9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS 14	FEB 28	TOXCENTER reloaded with enhancements
NEWS 15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS 16	MAR 01	INSPEC reloaded and enhanced
NEWS 17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 18	MAR 08	X.25 communication option no longer available after June 2006
NEWS 19	MAR 22	EMBASE is now updated on a daily basis
NEWS 20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 22	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:33:17 ON 20 APR 2006

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 11:33:50 ON 20 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Apr 2006 VOL 144 ISS 17
FILE LAST UPDATED: 19 Apr 2006 (20060419/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s us 2005-0182143/pn
L1 1 US 2005-0182143/PN
(US2005182143/PN)

=> sel rn
E1 THROUGH E3 ASSIGNED

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.49	2.70

FILE 'REGISTRY' ENTERED AT 11:34:08 ON 20 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 APR 2006 HIGHEST RN 881002-15-9
DICTIONARY FILE UPDATES: 18 APR 2006 HIGHEST RN 881002-15-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from  *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s e1-e3
             1 128607-22-7/BI
               (128607-22-7/RN)
             1 861926-89-8/BI
               (861926-89-8/RN)
             1 128585-01-3/BI
               (128585-01-3/RN)
L2           3 (128607-22-7/BI OR 861926-89-8/BI OR 128585-01-3/BI)

=> d 1-3

L2   ANSWER 1 OF 3  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   861926-89-8  REGISTRY
ED   Entered STN:  29 Aug 2005
CN   Ethanol, 2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]- (9CI)  (CA INDEX
     NAME)
FS   3D CONCORD
MF   C24 H23 Cl O2
SR   CA
LC   STN Files:   CA, CAPLUS, USPATFULL
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2   ANSWER 2 OF 3  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   128607-22-7  REGISTRY
ED   Entered STN:  03 Aug 1990
CN   Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]- (9CI)  (CA
     INDEX NAME)
OTHER CA INDEX NAMES:
CN   Ethanol, 2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-, (Z)-
```

OTHER NAMES:
CN Fc 1271
CN FC 1271a
CN Ospemifene
FS STEREOSEARCH
MF C24 H23 Cl O2
SR CA
LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, CA, CAPLUS, CIN, CSCHEM, EMBASE, IMSDRUGNEWS, IMSRESEARCH, IPA, PHAR, PROUSDDR, TOXCENTER, USAN, USPAT2, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

50 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
50 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2006 ACS on STN
RN **128585-01-3** REGISTRY
ED Entered STN: 03 Aug 1990
CN Phenol, 4-[(1Z)-4-chloro-1-[4-(2-hydroxyethoxy)phenyl]-2-phenyl-1-butenyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 4-[4-chloro-1-[4-(2-hydroxyethoxy)phenyl]-2-phenyl-1-butenyl]-, (Z)-
OTHER NAMES:
CN Fc 1272
FS STEREOSEARCH
MF C24 H23 Cl O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

11 REFERENCES IN FILE CA (1907 TO DATE)

11 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s 128607-22-7/rn
L3            1 128607-22-7/RN

=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         6.58       9.28

FILE 'CAPLUS' ENTERED AT 11:35:24 ON 20 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 20 Apr 2006  VOL 144 ISS 17
FILE LAST UPDATED: 19 Apr 2006  (20060419/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 128607-22-7/rn
            50 128607-22-7
             5 128607-22-7D
L4           50 128607-22-7/RN
                (128607-22-7 (NOTL) 128607-22-7D )

=> s l4 and bioavailability
         51500 BIOAVAILABILITY
L5           4 L4 AND BIOAVAILABILITY

=> d 1-4 bib abs hitstr

L5   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2005:1195865  CAPLUS
DN   143:466162
TI   Novel oral formulations of ospemifene
IN   Lehtola, Veli-Matti; Anttila, Markku
PA   Hormos Medical Corporation, Finland
SO   PCT Int. Appl., 16 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    -------------------     --------
PI   WO 2005105052        A1    20051110    WO 2005-FI131           20050302
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
```

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

PRAI US 2004-567525P P 20040504

AB This invention relates to a liquid or semisolid oral drug formulation comprising ospemifene or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester or a metabolite thereof, in combination with a pharmaceutically acceptable carrier. Thus, the absorption of ospemifene from oral solution containing 60 mg ospemifene in a mixture of ethanol-PEG-propylene glycol (2.7:1:2.5) was much faster and the **bioavailability** much higher than from tablets and hard capsules in healthy individuals. Addnl., the variability of the pharmacokinetic parameters for oral solution decreased.

IT **128607-22-7**, Ospemifene
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid or semisolid oral formulations of ospemifene with improved **bioavailability**)

RN 128607-22-7 CAPLUS

CN Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:823323 CAPLUS

DN 143:186685

TI Method for enhancing the **bioavailability** of oral ospemifene in connection with food intake

IN Anttila, Markku

PA Hormos Medical Corporation, Finland

SO U.S. Pat. Appl. Publ., 7 pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005182143	A1	20050818	US 2004-777211	20040213
WO 2005077350	A1	20050825	WO 2005-FI18	20050114

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,

RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2004-777211 A 20040213

GI



I

AB The invention discloses a method for enhancing the **bioavailability** of a therapeutically active compound I, or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester, or a metabolite thereof, wherein the compound is administered orally to the individual in connection with the intake of food.

IT **128607-22-7**, Ospemifene
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral ospemifene **bioavailability** enhancement in connection with food intake)

RN 128607-22-7 CAPLUS

CN Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:995989 CAPLUS

DN 142:747

TI Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions

IN Hansen, Christian; Nilsson, Henrik

PA Nordic Bone A/S, Den.; Osteologix A/S; Christgau, Stephan

SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
---	---	---	---	---

PI WO 2004098618 A2 20041118 WO 2004-DK327 20040506
WO 2004098618 A3 20050324
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2004237438 A1 20041118 AU 2004-237438 20040506
CA 2524610 AA 20041118 CA 2004-2524610 20040506
EP 1622630 A2 20060208 EP 2004-731315 20040506
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
WO 2005108339 A2 20051117 WO 2005-DK307 20050505
WO 2005108339 A3 20051229
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI DK 2003-691 A 20030507
DK 2003-931 A 20030620
DK 2003-1819 A 20031209
US 2003-528548P P 20031209
WO 2004-DK326 A 20040506
WO 2004-DK327 W 20040506
WO 2004-DK328 A 20040506
DK 2004-1708 A 20041105

AB A combination treatment, wherein a strontium-containing compound together with one or more active substances capable of reducing the incidence of bone fracture and/or increasing bone d. and/or improving healing of fractured bone and/or improving bone quality are administered for use in the treatment and/or prophylaxis of cartilage and/or bone conditions.

IT **128607-22-7**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination treatment with strontium for prophylaxis and/or treatment of cartilage and/or bone conditions)

RN 128607-22-7 CAPLUS
CN Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:351117 CAPLUS
DN 139:332048
TI Pharmacokinetics of selective estrogen receptor modulators
AU Morello, Karla C.; Wurz, Gregory T.; DeGregorio, Michael W.
CS Department of Internal Medicine, Division of Hematology/Oncology, Cancer Center, University of California, Davis, CA, USA
SO Clinical Pharmacokinetics (2003), 42(4), 361-372
CODEN: CPKNDH; ISSN: 0312-5963
PB Adis International Ltd.
DT Journal; General Review
LA English
AB A review. Selective estrogen receptor modulators (SERMs) are a class of compds. used to treat and prevent breast cancer and osteoporosis. SERMs currently approved for use in patients include tamoxifen, toremifene and raloxifene. These compds. are well tolerated in patients, and the most common adverse effects experienced in patients undergoing SERM therapy include vasomotor symptoms such as hot flashes and vaginal discharge. New SERMs currently under development for use in the treatment and prevention of osteoporosis and breast cancer include ospemifene, a derivative of toremifene, and arzoxifene, a compound very similar in structure to raloxifene. SERMs are administered orally at doses ranging from 20 to 60 mg/day. Tamoxifen and toremifene have a **bioavailability** of approx. 100%, whereas that of raloxifene is only 2%. SERMs are very highly bound to plasma proteins (>95%). Tamoxifen and toremifene are metabolized by the cytochrome P 450 enzyme system, and raloxifene is metabolized by glucuronide conjugation. The terminal elimination half-lives of these drugs range from 27.7 h to 7 days. The pharmacokinetics of these compds. are affected in hepatically impaired patients, but not in renally impaired patients. SERMs have several potential drug interactions with other agents, such as warfarin, rifampicin (rifampin), cholestyramine and aromatase inhibitors.
IT **128607-22-7**, Ospemifene
RL: ADV (Adverse effect, including toxicity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacokinetics of selective estrogen receptor modulators)
RN 128607-22-7 CAPLUS
CN Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s l4
50 128607-22-7
5 128607-22-7D
L6 50 128607-22-7/RN
(128607-22-7 (NOTL) 128607-22-7D)

=> d 1-50 ti

L6 ANSWER 1 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

TI Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency

L6 ANSWER 2 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI A method of improving treatments in rheumatic and arthritic diseases using strontium salts

L6 ANSWER 3 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI 5-LOX inhibitors and bone and cartilage beneficial agent combinations for arthritis, osteoporosis, or pain

L6 ANSWER 4 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ

L6 ANSWER 5 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice

L6 ANSWER 6 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Novel oral formulations of ospemifene

L6 ANSWER 7 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Pharmaceutical compositions containing selective estrogen receptor modulators for the treatment of alzheimer's disease

L6 ANSWER 8 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method using triphenylalkene or triphenylalkane selective estrogen receptor modulators for treatment or prevention of osteoporosis in individuals with high bone turnover

L6 ANSWER 9 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Solid formulations of ospemifene

L6 ANSWER 10 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method for enhancing the bioavailability of oral ospemifene in connection with food intake

L6 ANSWER 11 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Ospemifene as a chemopreventive agent

L6 ANSWER 12 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions

L6 ANSWER 13 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Selective estrogen receptor modulators prevent neointima formation after vascular injury

L6 ANSWER 14 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women

L6 ANSWER 15 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Ospemifene (Hormos)

L6 ANSWER 16 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Ospemifene: Treatment of postmenopausal syndrome treatment of osteoporosis selective estrogen receptor modulator

L6 ANSWER 17 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Comparative study of the short-term effects of a novel selective estrogen receptor modulator, ospemifene, and raloxifene and tamoxifen on rat uterus

L6 ANSWER 18 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women

L6 ANSWER 19 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods and composition for treating decreased libido in women with estrogenic components

L6 ANSWER 20 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Treatment with selective estrogen receptor modulators (SERMs) in conjunction with progestins to suppress cartilage degeneration

L6 ANSWER 21 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Pharmacokinetics of selective estrogen receptor modulators

L6 ANSWER 22 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women

L6 ANSWER 23 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Estrogen receptor β-based hypertension treatment and assay

L6 ANSWER 24 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women

L6 ANSWER 25 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method for in vitro screening of drug candidates useful for the prevention of bone resorption

L6 ANSWER 26 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Cone voltage and collision cell collision-induced dissociation study of triphenylethylenes of pharmaceutical interest

L6 ANSWER 27 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Selective estrogen receptor modulators in combination with estrogens for therapeutic use

L6 ANSWER 28 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer

L6 ANSWER 29 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method using (deaminohydroxy)toremifene for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause

L6 ANSWER 30 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator

L6 ANSWER 31 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene

L6 ANSWER 32 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats

L6 ANSWER 33 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture

L6 ANSWER 34 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Quantitative analysis of Z-2-[4-(4-chloro-1,2-diphenyl-but-1-

enyl)phenoxy]ethanol in human plasma using high-performance liquid chromatography

L6 ANSWER 35 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Z-2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol as serum cholesterol lowering agent, preparation thereof, and pharmaceutical compositions

L6 ANSWER 36 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI High-dose toremifene in advanced renal-cell carcinoma

L6 ANSWER 37 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Retention behavior of triphenylethylene derivatives in reverse phase liquid chromatography

L6 ANSWER 38 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Triphenylethylenes for the prevention and treatment of osteoporosis

L6 ANSWER 39 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI A study of the structural basis of the carcinogenicity of tamoxifen, toremifene and their metabolites

L6 ANSWER 40 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes

L6 ANSWER 41 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI High performance liquid chromatography of toremifene and metabolites

L6 ANSWER 42 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI High-performance liquid chromatographic analysis of tamoxifen, toremifene and their major human metabolites

L6 ANSWER 43 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells

L6 ANSWER 44 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Comparative affinity of steroidal and nonsteroidal antiestrogens, cholesterol derivatives and compounds with a dialkylamino side chain for the rat liver antiestrogen binding site

L6 ANSWER 45 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI High-performance liquid chromatographic method for the determination of toremifene and its major human metabolites

L6 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Biochemical and pharmacological effects of toremifene metabolites

L6 ANSWER 47 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI In vitro and in vivo binding of toremifene and its metabolites in rat uterus

L6 ANSWER 48 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Metabolism of toremifene in the rat

L6 ANSWER 49 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Pharmacokinetics of toremifene

L6 ANSWER 50 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
TI Quantitative analysis of toremifene metabolites in biological specimens by high-performance liquid chromatography

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	48.07	57.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.00	-3.00

STN INTERNATIONAL LOGOFF AT 11:37:18 ON 20 APR 2006

10/777211

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	0	ospimefene	USPAT	OR	ON	2006/04/20 12:05
L2	2	"9607402"	USPAT	OR	ON	2006/04/20 12:14
L8	1	"9200743"	USPAT	OR	ON	2006/04/20 12:56
L12	1	"01036360"	USPAT	OR	ON	2006/04/20 12:58
L13	3	"0207718"	USPAT	OR	ON	2006/04/20 13:19
L14	0	"200207718"	USPAT	OR	ON	2006/04/20 13:19
L15	4	"5352699"	USPAT	OR	ON	2006/04/20 13:22
L16	2	"5747059"	USPAT	OR	ON	2006/04/20 13:24
L17	0	"2001034340"	USPAT	OR	ON	2006/04/20 13:24
L18	1	"01034340"	USPAT	OR	ON	2006/04/20 13:25
L19	0	"2001034340"	USPAT	OR	ON	2006/04/20 13:25
L20	0	"2001034340"	US-PGPUB; USPAT	OR	ON	2006/04/20 13:25
L21	1	"01034340"	US-PGPUB; USPAT	OR	ON	2006/04/20 13:25
L23	28	bazedoxifene	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/04/20 13:26
L25	9	"6245819"	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/04/20 15:04
L26	2	"6984665"	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/04/20 15:04
S1	646948	bone loss	USPAT	OR	ON	2006/04/20 10:41
S2	26093	osteoporosis	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/15 14:04
S3	6695	S1 and S2	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/15 14:07
S4	1	wo-2003105834-$.did.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/15 14:16

EAST Search History

S5	13	bazedoxifene	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/15 14:17
S7	599639	S5 and bone loss	USPAT	OR	ON	2005/04/15 14:18
S9	1	"5998402".pn.	USPAT	OR	ON	2005/06/27 17:18
S10	1	"6649598".pn.	USPAT	OR	ON	2005/04/25 16:15
S11	14	bazedoxifene	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/25 16:32
S12	15	bazedoxifene	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/12/12 17:32
S13	539173	bazedoxifene acetate	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/06/27 17:54
S14	1158990	bone loss	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/06/27 17:54
S15	139824	S13 and S14	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/06/27 17:54
S16	27059	osteoporosis	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/06/27 18:59
S17	605876	S12 and bone loss	USPAT	OR	ON	2005/06/27 18:59
S18	4200	S17 and S16	USPAT	OR	ON	2005/06/27 19:00
S19	1972	bazedoxifene same bone loss same osteoporosis	USPAT	OR	ON	2005/06/27 19:44
S20	605876	bazedoxifene same bone loss	USPAT	OR	ON	2005/06/27 19:44
S21	32	"5998402"	USPAT	OR	ON	2005/12/12 15:07
S22	1	"6583170"	USPAT	OR	ON	2005/12/12 15:07
S23	1082140	bazedoxifene and bone loss	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/12/12 17:33
S24	24	(bazedoxifene) and (bone loss)	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/12/12 17:33

EAST Search History

S25	27	bazedoxifene	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/03/01 20:49
S26	2608	raloxifene	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/03/01 20:49
S27	1104010	raloxifene and bone loss	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/03/01 20:49
S28	1103706	raloxifene with bone loss	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/03/01 20:49
S29	458	(raloxifene) with (bone loss)	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/04/20 14:06